ArticleJournal of Alzheimer's disease & Parkinsonism2014
Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography.
Article in Journal of Alzheimer's disease & Parkinsonism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 30 citations in OpenAlex.
- Mitochondrial Complex I and β-Amyloid Peptide Interplay in Alzheimer's Disease: A Critical Review of New and Old Little Regarded Findings.International journal of molecular sciences · 2023Review
- Optical Redox Imaging of Ex Vivo Hippocampal Tissue Reveals Age-Dependent Alterations in the 5XFAD Mouse Model of Alzheimer's Disease.Metabolites · 2022Article
- The Association Between Acquired Color Deficiency and PET Imaging of Neurodegeneration in Mild Cognitive Impairment and Alzheimer Disease.Investigative ophthalmology & visual science · 2022Article
- Altered substrate metabolism in neurodegenerative disease: new insights from metabolic imaging.Journal of neuroinflammation · 2021Review
- Au nano-urchins enabled localized surface plasmon resonance sensing of beta amyloid fibrillation.Nanoscale advances · 2020Article
- The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease.Molecular neurobiology · 2020Review
- Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.Molecular neurobiology · 2017Review
- Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features.Journal of Alzheimer's disease : JAD · 2017Article
- Insight into the Molecular Imaging of Alzheimer's Disease.International journal of biomedical imaging · 2016Review
- The Potential of Metabolic Imaging.Seminars in nuclear medicine · 2016Review
- PET Imaging of Epigenetic Influences on Alzheimer's Disease.International journal of Alzheimer's disease · 2015Review
- Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology.Frontiers in neurology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Current Positron Emission Tomography (PET) biomarkers for Alzheimer's disease (AD) assess either neuronal function, or associated pathological features of this common neurodegenerative disease. The most widely accepted clinical PET tool for AD is 18-fluorodeoxyglucose PET (FDG-PET), which measures cerebral metabolic glucose utilization rate (CMRglc). FDG-PET is a marker of synaptic activity, neuronal function, and neuronal metabolic activity. AD is characterized by a distinct pattern of hypometabolism, as seen with the FDG images. This pattern can show variability across different subjects and is present before a patient is demented, specifically in amnestic mild cognitive impairment a clinical diagnosis defined as an intermediate state from normal aging to dementia. In addition to FDG PET, novel PET approaches assess known pathological hallmarks of AD including extracellular amyloid-beta plaques (Aβ) and intracellular neurofibrillary tangles composed of tau fibrils. Already, amyloid PET imaging is a tool that allows
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.